Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database.

BACKGROUND The human epidermal growth factor receptor 2 (HER2)-targeted therapy trastuzumab deruxtecan has demonstrated significantly improved efficacy versus chemotherapy in HER2-low or -ultralow, hormone receptor (HR)-positive metastatic breast cancer (mBC) following endocrine therapy (ET). This study describes curre...

W. Jacot, P. Macouillard, Su-Yuan Zhang et al. · 0 citations
Sep 2026

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.

BACKGROUND Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer and a low-risk 70-gene signature (MammaPrint®). However, the contribution of the 70-gene signature in high-risk subgroups by nodal involvemen...

Robbert C. A. M. Gielen, C. Poncet, L. J. van 't Veer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.